SEC Filings

KERYX BIOPHARMACEUTICALS INC filed this Form 424B5 on 07/27/2017
Entire Document

Table of Contents


The following summary of certain provisions of our preferred stock does not purport to be complete. You should refer to our amended and restated certificate of incorporation and our amended and restated bylaws, both of which are included as exhibits to the registration statement of which this prospectus is a part. The summary below is also qualified by provisions of applicable law.


We are authorized to issue 5,000,000 shares of preferred stock, par value $0.001 per share. As of October 31, 2016, no shares of our preferred stock were outstanding or designated.

Our board of directors may, with approval of the action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors and with stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock.

If we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include:


    the title and stated value;


    the number of shares offered, the liquidation preference, if any, per share and the purchase price;


    the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;


    whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;


    the procedures for any auction and remarketing, if any;


    the provisions for a sinking fund, if any;


    the provisions for redemption, if applicable;


    any listing of the preferred stock on any securities exchange or market;


    whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated) and conversion period;


    whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated) and exchange period;


    voting rights, if any, of the preferred stock;


    a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock;


    the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and